strictly scientific, reason was the lack of stimulus from major pharmaceutical companies to take the risks involved in developing new nonmonoaminergic drugs for depression. Differently from other drug fields (eg, cancer, cardiovascular diseases) much of the effort in recent, times was directed toward replication and implementation of already known mechanisms (eg, “me-too” drugs). However, with all the limitations
exposed above, a good number of new compounds are in development. We have listed here only new Inhibitors,research,lifescience,medical drug classes that have been in development for some time (some of them for quite a long time) and possibly recent, new drugs will be missing here. Most of these compounds are based on peptidergic, glutamatergic or circadian rhythm-related mechanisms, but a few still relate to a monoaminergic mechanism (Table III). Table III Table III. New antidepressants in development or marketed. NK, neurokinin; NMDÀ, N-methyl-D-asparticacid; CRF, corticotrophinreleasing factor; AMPA, alpha-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid; mGlun glutamate; Inhibitors,research,lifescience,medical 5-HT, serotonin NK-1 receptor and CRF-1 receptor antagonists have had a somewhat, troubled history. Both drug classes have in turn raised much hope and most, companies have had (some still have) these compounds
in their pipeline. In the case of NK-1 antagonists, one of them (M.K-869) did not separate from placebo in phase Inhibitors,research,lifescience,medical II clinical studies and the development
was discontinued. However, the hypothesis of using NK-1 antagonists for add-on strategy with SSRIs or SNRIs is still pursued. Antagonists of the CRF1 receptor Inhibitors,research,lifescience,medical have also been in development for quite some time. After preclinical development, one of these compounds (R121919) Inhibitors,research,lifescience,medical showed antidepressant efficacy in an open-label clinical trial, but later was dropped owing to hepatotoxicity. Other compounds in this class are still in development. Compounds acting on glutamate transmission represent a large and variegated class of potential antidepressants.71 As addressed above, the interest in glutamate as a potential target in depression and mood disorder is not new; however, recently this interest, was revived by several key findings, such as the many morphological and functional changes found with depression in areas where glutamate transmission predominates, the documented effects of stress on glutamatergic neurons and circuits, the striking sustained antidepressant Rolziracetam effect of a single infusion of ketamine (see above). The psychotomimetic properties of ketamine are a limit to its clinical use, but similar compounds less endowed with these properties would be interesting drugs that could greatly fasten the onset of action. Weaker NM’DA antagonists, such as GDC-0941 solubility dmso memantine, or compounds acting on modulatory sites of the NMDA receptor could be viable alternatives to reduce NMDAmediated throughput.